靶向微波消融治疗前列腺癌(FOSTINE1b):一项前瞻性「消融后切除」研究
这项前瞻性、单中心、介入性IIa期「消融后切除」研究纳入11例局限性前列腺癌患者,在清醒镇静下经直肠使用单根TATO 18-G天线行Trinity系统靶向微波消融,其中9例随后接受机器人辅助根治性前列腺切除术。结果显示无严重不良事件,泌尿、性及射精功能未见下降,手术标本证实消融区完全坏死。
要点
- 靶向微波消融在门诊清醒镇静下完成,所有患者当日出院
- 7天和1个月随访未见CTCAE≥3级严重不良事件
- 手术标本证实,功率强度>10 W时消融区完全坏死,无存活细胞
核心结论
- 经Trinity系统行靶向微波消融治疗局限性前列腺癌是安全、可行的操作,手术标本显示消融区内完全坏死的证据。
研究设计与样本
- 前瞻性、单中心、介入性IIa期研究,采用「消融后切除」设计;共11例局限性前列腺癌患者接受Trinity系统靶向微波消融,使用单根经直肠TATO 18-G天线、不同治疗方案,在门诊清醒镇静下完成;消融后7天行磁共振成像(MRI),1个月后行机器人辅助根治性前列腺切除术(RARP);9例接受RARP,2例在消融后撤回知情同意并选择主动监测方案。
主要发现
- 靶向微波消融均成功实施,所有患者当日出院;7天和1个月随访未报告CTCAE≥3级严重不良事件。
- 泌尿、性及射精功能结局均未见下降;T1加权MRI显示消融区清晰、边界明确。
- RARP操作顺利,尤其在后侧平面分离时;未发生术中并发症;手术标本组织病理学评估证实无存活细胞,功率强度>10 W时消融区完全坏死。
- 消融区体积测量显示,消融时三维分割的虚拟消融区(中位体积2 mL)与MRI(中位体积1.923 mL)之间无明显差异;而手术标本中位体积0.221 mL,显著缩小。
关键数值与推荐
- 手术标本证实消融区完全坏死的条件为消融时使用功率强度>10 W。
- 消融时虚拟消融区中位体积2 mL,MRI中位体积1.923 mL,两者无明显差异;手术标本中位体积0.221 mL,显著缩小。
临床怎么用
- 原文结论认为,经Trinity系统行靶向微波消融治疗局限性前列腺癌是安全、可行的操作,手术标本显示消融区内完全坏死的证据;原文未据此给出进一步临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess histopathological outcomes, as well as feasibility and safety of targeted microwave ablation (TMA) via the Trinity® system (KOELIS, La Tronche, France). PATIENTS AND METHODS: Prospective, single-institution, interventional Phase IIa study with an 'ablate-and-resect' design. In all, 11 patients diagnosed with localised prostate cancer (PCa) underwent TMA via the Trinity system under conscious sedation in an outpatient setting using a single transrectal TATO® 18-G antenna with different treatment regimens. Magnetic resonance imaging (MRI) and robot-assisted radical prostatectomy (RARP) were conducted at 7 days and 1 month after TMA, respectively. Nine patients received RARP, and two patients chose to withdraw their consent following TMA. These men chose an active surveillance protocol upon confirmation of a low-risk prostate cancer diagnosis. Functional outcomes and adverse events were evaluated at baseline and follow-up visits using validated questionnaires. Prostate volumetry and confirmation of necrosis were carried out through MRI and whole-mount histopathological examination. RESULTS: The TMA was successfully executed, and all patients were discharged on the same day. No severe adverse events (Common Terminology Criteria for Adverse Events Grade ≥3) were reported at the 7-day and 1-month follow-up visits. Additionally, no declines were observed in urinary, sexual and ejaculation functional outcomes. T1-weighted MRI revealed clear and well-defined ablation zones. The RARP was executed without difficulty, particularly during the dissection of the posterior plane. As a result, no intraoperative complications were encountered. Histopathological assessment on surgical specimens confirmed the absence of viable cells, indicating complete necrosis of the ablative zone if a power intensity >10 W was used during TMA. Ablation zone volumetry revealed no notable distinctions between the three-dimensional segmentation of the virtual ablation zone at TMA (median volume: 2 mL) and MRI (median volume: 1.923 mL). Conversely, a significant reduction was noted in the surgical specimen (median volume: 0.221 mL). CONCLUSIONS: Targeted microwave ablation via the Trinity system for localised PCa treatment proves to be a secure and feasible procedure, with complete necrosis evidence within the ablation zone on surgical specimens.
引用
- Peltier A, van Velthoven R, Baudewyns A, et al. Targeted microwave ablation for prostate cancer (FOSTINE1b): a prospective 'ablate-and-resect' study. BJU Int. 2024. PMID: 38742416. doi:10.1111/bju.16385
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。